Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Malnutrition and Prognosis in Elderly Patients with Chronic Heart Failure
Author(s): Mohammed El-Sheikh , Nora Olsen El Caidi , Aginsha Kandiah , et al Added: 3 months ago

Cardiovascular Renal Metabolic

Heart Failure
EMPA-KIDNEY: Empagliflozin in Patients with Chronic Kidney Disease
Author(s): William Herrington Added: 1 year ago
Long-term cardio-renal outcomes investigating empagliflozin (Boehringer Ingelheim) on kidney disease progression (KDP) or cardiovascular death in patients with pre-existing chronic kidney disease.In this short interview, Prof William Herrington (Nuffield Department of Population Health, University of Oxford, Oxford, UK) discusses the findings from EMPA-KIDNEY (NCT03594110).EMPA-KIDNEY is an… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
Post-PE Syndrome and Transcatheter Therapy
Author(s): Belén Biscotti Rodil , Juan Duarte Torres , Irene Martín de Miguel , et al Added: 1 month ago

Heart Failure
Emerging Therapies for Obstructive Hypertrophic Cardiomyopathy
Author(s): Emily Li-Wen Chu , Daniel Seung Kim , Ahmad Masri Added: 3 months ago

Heart Failure

Intervention
Heart Disease in Pregnancy: Maternal and Neonatal Risk
Author(s): Rofila Dita Karmia , Mefri Yanni , Yusrawati , et al Added: 1 month ago

Electrophysiology & Arrhythmia

Heart Failure
2023 ESC Guidelines Update: Acute & Chronic Heart Failure
Author(s): Giuseppe Rosano , Harriette Van Spall Added: 2 years ago
ESC 23 – Late-Breaker host, Dr Harriette Van Spall (McMaster University, CA) is joined by Prof Giuseppe Rosano (St George’s Hospitals NHS Trust University of London, UK), President of HFA to distil the key messages from the 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Prof Rosano summarises the retained ejection fraction… View more

Guidelines & Statements

Heart Failure
Phrenic Nerve Stimulation for Central Sleep Apnoea
Author(s): Jonathan Na , Miguel Valderrábano , Paul Schurmann Added: 1 month ago

Electrophysiology & Arrhythmia

Heart Failure
AHA 25: MAPLE-HCM Responder Analysis
Author(s): Andrew Wang Added: 3 months ago
AHA Scientific Sessions 2025 – MAPLE-HCM responder analysis shows aficamten monotherapy led to greater treatment effect when compared to metoprolol monotherapy.Dr Andrew Wang (Duke University Medical Center, Durham, NC, US) presents a responder analysis from the MAPLE-HCM trial (NCT05767346), examining clinical responses to aficamten monotherapy versus metoprolol in patients with obstructive… View more

Heart Failure
ESC 25: The ODYSSEY-HCM Study
Author(s): Milind Y Desai Added: 5 months ago
ESC Congress 2025 - ODYSSEY-HCM finds no improvements in patients with non-obstructive cardiomyopathy when treated with mavacamten.Dr Milind Desai (Cleveland Clinic, US) joins us to discuss findings from the ODYSSEY-HCM trial, evaluating the safety, tolerability, and efficacy of mavacamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy.The ODYSSEY-HCM study was a… View more

Heart Failure
MAPLE-HCM: Aficamten Outperforms Beta-Blocker in Obstructive Hypertrophic Cardiomyopathy
Added: 5 months ago Source:  Radcliffe Cardiology
Two phase 3 trials presented at the European Society of Cardiology Congress 2025 have provided new insights into the role of myosin inhibitors for hypertrophic cardiomyopathy (HCM), with one trial demonstrating superiority over standard care in obstructive HCM and another failing to meet its primary endpoints in the non-obstructive form of the disease.¹˒²The MAPLE-HCM trial found that the cardiac… View more

Guidelines & Statements

Heart Failure